[16] While some participants in clinical studies have reported menstrual changes, these are generally attributed to the metabolic effects of weight loss rather than direct drug action on reproductive tissues, and are not classified as common adverse effects in the UK product information for GLP-1 medications
In August 2025, semaglutide (Wegovy) received FDA accelerated approval for MASH with F2 to F3 fibrosis based on the results of the ESSENCE trial
Wilmes L, Caputi V, Bastiaanssen TFS, Collins JM, Crispie F, Cotter PD, et al
While awaiting peptide regulatory approval and veterinary guidelines, support your bulldogs health today with Dr
As great as your friends and family are, they may not be able to fully understand what youre going through
Some patients taper to a lower maintenance dose rather than stopping